Lineage Cell Therapeutics Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Lineage Cell Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.50. The average 1-year stock price forecast is 347.15% higher than the current stock price, while the lowest is $3.00 (+143.90%) and the highest is $9.00 (+631.71%).

Price Target: $5.50 (+347.15%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$5.50	$4.50	$9.00
Change	+143.90%	+347.15%	+265.85%	+631.71%

Analyst Ratings

The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	5	5	5	5	6	5
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $9	Buy	Reiterates	$9	+631.71%	May 26, 2026
Michael Okunewitch Maxim Group	Maxim Group	Buy Maintains $3	Buy	Maintains	$3	+143.90%	May 15, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $9	Buy	Maintains	$9	+631.71%	May 13, 2026
Mayank Mamtani B. Riley Securities	B. Riley Securities	Buy Maintains $3 → $4	Buy	Maintains	$3 → $4	+225.20%	Mar 25, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

17.94M

from 14.56M

23.23%

from 14.56M

Revenue Next Year

18.09M

from 17.94M

0.87%

from 17.94M

EPS This Year

-0.07

from -0.22

EPS Next Year

-0.09

from -0.07

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	4.34M	14.70M	8.95M	9.50M	14.56M	17.94M
Revenue Growth	137.73%	238.70%	-39.16%	6.19%	53.24%	23.23%
Gross Profit	2.92M	13.98M	-7.43M	-3.31M	-3.32M	17.64M
Gross Margin	67.15%	95.05%	-83.07%	-34.81%	-22.80%	98.33%
Operating Income	-49.21M	-22.52M	-21.20M	-21.48M	-21.78M	-24.28M
Net Income	-43.02M	-26.27M	-21.49M	-18.61M	-63.53M	-23.79M
EPS	-	-	-	-	-0.22	-0.07
Free Cash Flow	-37.46M	13.34M	-10.37M	-12.80M	-11.18M	-9.30M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	38.4M
Avg	17.9M
Low	1.7M

Revenue Growth

Revenue Growth	2026	2027	2028
High	163.8%
Avg	23.2%
Low	-88.1%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.07
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-